Indolyl derivatives as liver-X-receptor (LXR) modulators

Details Indolyl derivatives as liver-X-receptor (LXR) modulators Indolyl derivatives as liver-X-receptor (LXR) modulators

2007-02-06

2007-02-06

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S235000, C548S409000, C548S468000, C548S490000, C546S271400, C514S374000, C514S414000, C514S415000

Reexamination Certificate

active

11115942

ABSTRACT:
The invention relates to compounds of formula (I):and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim1.These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.

REFERENCES:
patent: 4251659 (1981-02-01), Aldrich et al.
patent: 6472386 (2002-10-01), Kodama et al.
patent: 1583249 (1981-01-01), None
patent: 9095482 (1997-08-01), None
patent: WO97019311 (1997-05-01), None
patent: WO200292084 (2002-11-01), None
patent: WO2004006922 (2004-01-01), None
Willy et al., Genes Dev. 1995, 9:1033-45.
Song et al., Proc Natl Acad Sci USA.1994, 91:10809-13.
Miller Ne., Lipids 1978,13:914-9.
Gordon et al., Am J Med. 1977, 62:707-14.
Lund et al., Arterioscler. Thromb. Vasc. Biol. 2003, 23:1169-77.
Joseph and Tontonoz, Curr. Opin. Pharmacol. 2003, 3:192-7.
Cao et al., J Biol Chem. 2003, 278:1131-6.
Chini et al., J. Org. Chem., 1991, 56(20) 5939-5942.
Duran Pachon et al., Tet. Lett., 2003, 44(32) 6025-6027.
Sundermeyer et al., Chemistry an European Journal, 2003, 9 (8), 1828-1836.
Brown et al., Tet. Lett., 2001, 2 (6), 983-985.
Kanekiyo et al., Heterocycles, 2000, 53 (9), 1877-1880.
Pearlstein et al., Bioorg. and Med. Chem. Lett., 2003, 13, 1829-1835.
Mewshaw et al., Bioorg. and Med. Chem. Lett., 2002, 12, 307-310.
Sakagani et al., Synlett. 1996, 163-164.
Maryanoff et al., Chem. Rev., 1989, 89, 863-927.
Saravan et al., Tet. Lett. 1998, 39 (22), 3823-3824.
Togo et al. Syn. Lett., 2003, 702-704.
Durley et al., J. Med. Chem., 2002, 45, 18, 3891-3904.
Tian et al., Org. Lett., 3, 12, 2001, 1929-1932.
Cynkowski et al., J. Chem. Soc. Chem. Commun., 1995, 2335-2336.
Faul et al., Heterocycles, 2001, 55 (4), 689-704.
Olofsson et al. J. Org. Chem., 1998, 65 (15), 5076-5079.
Buchwald et al., J. Org. Chem., 2000, 65 ( 4), 1158-1174.
Takagi et al., Chem. Lett., 1989, 11, 1957-58.
Bennett, D.J., et al., Expert Opin. Ther. Patents, vol. 14, No. 7, pp. 967-982 (2004), XP002342352.

Affiliated with

Also associated with

Rating

Indolyl derivatives as liver-X-receptor (LXR) modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indolyl derivatives as liver-X-receptor (LXR) modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolyl derivatives as liver-X-receptor (LXR) modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3833132